(Q38707726)

5 September 2017

Opioid antagonists in broadly defined behavioral addictions: a narrative review (English)

1 reference

5 September 2017

0 references

Leonardo F. Fontenelle

object named as

Leonardo F Fontenelle

series ordinal

2

0 references

author name string

Marcelo Piquet-Pessôa

series ordinal

1

1 reference

PubMed ID

26798982

5 September 2017

language of work or name

English

0 references

publication date

22 January 2016

1 reference

Expert Opinion on Pharmacotherapy

5 September 2017

1 reference

5 September 2017

17

1 reference

5 September 2017

6

1 reference

5 September 2017

835-844

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

5 September 2017

1 reference

An overview of and rationale for changes proposed for pathological gambling in DSM-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Impaired Decision-Making, Higher Impulsivity, and Drug Severity in Substance Dependence and Pathological Gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Impulsive action and impulsive choice across substance and behavioral addictions: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Reward pathway dysfunction in gambling disorder: A meta-analysis of functional magnetic resonance imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Neural correlates of substance abuse: reduced functional connectivity between areas underlying reward and cognitive control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Neurocircuitry of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Kleptomania: clinical characteristics and relationship to substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Evaluation and treatment of sex addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Compulsive buying disorder: a review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

The addictive dimensionality of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Internet sex addiction treated with naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

The neural circuitry of reward and its relevance to psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Treatment of Gambling Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Alteration of ethanol self-administration by naltrexone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Nalmefene: a review of its use in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Naltrexone and nalmefene: any meaningful difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Suicidal ideation and suicide attempts in treatment-seeking pathological gamblers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Gambling problems and health functioning in individuals receiving disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

An empirical typology of lifetime and current gambling behaviors: association with health status of older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

An open naltrexone treatment study in pathological gambling disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Commentary on Subbaraman et al. (2013) [corrected]: cravings as a mediator and moderator of drinking outcomes in the COMBINE Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Cravings as a mediator and moderator of drinking outcomes in the COMBINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Meta-analysis: pharmacological treatment of pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Overview of Kleptomania and Phenomenological Description of 40 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Suicide attempts in 107 adolescents and adults with kleptomania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Hypersexual disorder: a proposed diagnosis for DSM-V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Diagnosis, assessment, and treatment of hypersexuality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Opioids and sexual reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Treatment of compulsive sexual behaviour with naltrexone and serotonin reuptake inhibitors: two case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Treatment of fetishism with naltrexone: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Treatment of Compulsive Pornography Use With Naltrexone: A Case Report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

New and emerging drug molecules against obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

The Global Epidemic of Obesity: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

A new biomarker of hedonic eating? A preliminary investigation of cortisol and nausea responses to acute opioid blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Hormonal and neural mechanisms of food reward, eating behaviour and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Opioid system in the medial prefrontal cortex mediates binge-like eating

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Dopamine D1 and μ-opioid receptor antagonism blocks anticipatory 50 kHz ultrasonic vocalizations induced by palatable food cues in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Effects of baclofen and naltrexone, alone and in combination, on the consumption of palatable food in male rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

21 January 2018

Pathologic skin picking

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

21 January 2018

Skin picking disorder.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Commentary on: Are we overpathologizing everyday life? A tenable blueprint for behavioral addiction research. On the slippery slopes: The case of gambling addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Pharmacological treatments in pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

The diagnosis of mental disorders: the problem of reification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Research domain criteria (RDoC): toward a new classification framework for research on mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Alcohol addiction and the mu-opioid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Opioid Antagonists in the Treatment of Impulse-Control Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

Three cases of compulsive buying treated with naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2016.1145660

10.1517/14656566.2016.1145660

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26798982